Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.41 |
| ▸ | ANPEP | P15144 | 7/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 3/20 | 0.39 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LAP3 | P28838 | 4/20 | 0.35 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.34 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9100153 | 0.89 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL995721 | 0.89 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL8517612 | 0.85 | ALDH1A1 (0.36) | SLC7A5SLC1A3SLC1A2TSHRALDH1A1 | |
| SCHEMBL28742569 | 0.83 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL1585736 | 0.83 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL16062283 | 0.83 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL998946 | 0.83 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL16670559 | 0.83 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL7676359 | 0.83 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL7361839 | 0.83 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752141-B1 | ACETYL-LEUCINE FOR USE IN TREATING RESTLESS LEG SYNDROME | INTRABIO LTD (GB) | 2024-06-05 | — | — | EP | claimed |
| WO-2024079733-A1 | PROCESS FOR THE PREPARATION OF AMINOPYRIDAZINE DERIVATIVES | ADAMA MAKHTESHIM LTD. (IL) | 2024-04-18 | — | — | WO | claimed |
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | claimed |
| US-20210353637-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-11-18 | — | — | US | claimed |
| EP-3638370-B1 | TREATMENT OF MIGRAINE WITH ACETYL-LEUCINE | INTRABIO LTD (GB) | 2020-11-11 | — | — | EP | claimed |
| CN-110818620-A | Preparation method of meta-aromatic aldehyde | 安阳师范学院 | 2020-02-21 | — | — | CN | claimed |
| US-20190160027-A1 | SALBUTAMOL-CONTAINING OPHTHALMIC MEDICAMENT | REKIK RAOUF (TN) | 2019-05-30 | — | — | US | claimed |
| EP-3416631-B1 | THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES | INTRABIO LTD (GB) | 2019-05-15 | — | — | EP | claimed |
| EP-3257910-B1 | CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION, METHOD AND SYSTEM FOR COBALT-CONTAINING SUBSTRATE | VERSUM MAT US LLC (US) | 2019-03-27 | — | — | EP | claimed |
| EP-3359146-B1 | PHARMACEUTICAL COMPOSITIONS AND USES DIRECTED TO LYSOSOMAL STORAGE DISORDERS | INTRABIO LTD (GB) | 2019-01-23 | — | — | EP | claimed |
| EP-1571986-A2 | MANAGEMENT OF GASTRO-INTESTINAL DISORDERS | Oridion Breathid Ltd. (IL) | 2005-09-14 | — | — | EP | claimed |
| US-20050020931-A1 | Management of gastro-intestinal disorders | ORIDION BREATHID LTD. (IL) | 2005-01-27 | — | — | US | claimed |
| EP-1427325-A2 | MANAGEMENT OF GASTRO-INTESTINAL DISORDERS | Oridion Breathid Ltd. (IL) | 2004-06-16 | — | — | EP | claimed |
| WO-2004002307-A2 | MANAGEMENT OF GASTRO-INTESTINAL DISORDERS | ORIDION BREATHID LTD. (IL) | 2004-01-08 | — | — | WO | claimed |
| WO-2004002308-A2 | MANAGEMENT OF GASTRO-INTESTINAL DISORDERS | ORIDION BREATHID LTD. (IL) | 2004-01-08 | — | — | WO | claimed |
| EP-1006997-B1 | EFFERVESCENT MICROSPHERES AND METHOD FOR MAKING THEM | PF MEDICAMENT (FR) | 2003-07-02 | — | — | EP | claimed |
| WO-2003017818-A2 | MANAGEMENT OF GASTRO-INTESTINAL DISORDERS | ORIDION BREATHID LTD. (IL) | 2003-03-06 | — | — | WO | claimed |
| US-5519000-A | OLIGOPEPTIDE | CENTECOR, INC. (US) | 1996-05-21 | — | — | US | claimed |
| WO-1995026744-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CENTOCOR, INC. (US) | 1995-10-12 | — | — | WO | claimed |
| CN-1091952-A | Cosmetic composition | UNILEVER NV (NL) | 1994-09-14 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190160027-A1 | SALBUTAMOL-CONTAINING OPHTHALMIC MEDICAMENT | ADRB3, ADRB2, ADRB1 | SLC7A5 3602/4885SLC1A3 3140/4885SLC1A2 2077/4885 |
| US-20210353637-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | SLC7A5 3637/4885SLC1A3 1289/4885SLC1A2 801/4885 |
| US-11793817-B2 | Muscarinic M1 receptor agonists | CHRM1, CHRM2, CHRM3 | SLC7A5 3637/4885SLC1A3 1289/4885SLC1A2 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.